The efficacy of antipsychotic drug maintenance in reducing the risk of relapse among previously hospitalized schizophrenic patients has been well documented. However, data from an ongoing study comparing two cohorts of young first admission schizophrenics-one receiving neuroleptic-oriented treatment on the wards of a community mental health center (CMHC), the other an intensive interpersonal approach in a small homelike facility in the community (Soteria Housel-raise questions about the routine use of neuroleptics withJhis population. Our questioning of this practice is based on data analyzed from these two cohorts by means of the life table, a statistical technique appropriate for longitudinal studies. Data are presented in two ways: (1) The overall effectiveness of the two independent treatment programs (Soteria, N = 32. vs. CMHC, N = 36) is compared in terms of the probabilities of not being readmitted over the 2-year postdischarge interval. (2) Analyses that look at the influence of the original treatment setting and postdischarge antipsychotic drug status on readmission rates are presented. Program comparisons reveal Soteria patients to have a consistently higher survival rate than CMHC patients throughout 2 years postdischarge. . At 12 months postdischarge, the cumulative probability of remaining well (no readmissions) significantly favors the Soteria patients (p< .05, 
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). The overall results of the Soteria program were achieved dfspite the fact that all CMHC patients received neuroleptics during their original inpatient stays and about 50 perwnt were maintained on nea. roleptics up to the point of readml.. sion or study termination, whereas only 10 percent of Soteria subjects were treated with or maintained on neuroleptics. The survival rates by postdischarge drug status and program affiliation show the Soterianodrug group to have the highest proportion of survivors at almost every interval throughout 24 months, the CrvtHC drug-maintained group to have the lowest survival rate, and the CMHC unmaintained group to be surviving at a rate generally com· parable to the Soteria no-drug group.
Studies examining the efficacy of antipsychotic drug maintenance in reducing the risk of relapse among previously hospitalized psychiatric patients have flourished during the past decade. The general findings are-that neuroleptics provide the potential for truly preventive psychiatry. In a review of 24 controlled studies comparing relapse rates for schizophrenics on placebo and maintenance neuroleptics, Davis (1975) consistently found placebo patients to relapse more often than drugtreated patients. Hogarty and Ulrich (1977) found that although the risk of relapse declines with the passage of time, it is almost twice as high for placebo-treated patients (80 percent) as for drug-maintained patients (48 percent) after 2 years of treatment. Overall, relapse rates for schizophrenia, regardless of drug status, are 30-40 percent at6 months, 35-50 percent at I year, and 65-75 percent at 3-5 years (Anthony, Cohen, and Vitalo 1978 . . Own relapse rates for depot ,fluphenazine to be nearly -_ in the first year postdisJndicating that drug non-,. does not adequately exrelapse (Hogarty et aI., in ler et al. 1979) . These ld seem to run counter ,helming evidence in the literature that drug compliance is a crucial factor in reducing relapse.
In the present report, we will focus on the 2-year postdischarge risk of relapse in two relatively small groups of newly diagnosed, young, first admission schizophrenics: one initially treated with neuroleptics on the wards of a community mental health center (comparison group); the other without neuroleptic drugs in a small, homelike facility in the community, Soteria House (experimental group). Half of the comparison group patients were maintained on neuroleptics postdischarge (a clinical decision), whereas less than 10 percent of patients in the experimental group received maintenance drug therapy. Our study is not a controlled clinical drug trial, but rather a presentation of data for two groups representing contrasting treatment approaches to schizophrenia. We will attempt to identify predictors of relapse for our sample both by program affiliation and the combined influence of treatment program and postdischarge drug status.
Program Descriptions
Soteria. Soteria House is a 1915-vintage, 12-room residence located on a busy street in a "transitional" neighborhood of a San Francisco Bay Area city. Due primarily to licensing laws, the house can accommodate only six patients at a time. One or two patients are admitted each month. The staff consists of six paid nonprofessional therapists, a project director, and a quarter-time project psychiatrist. In general, two regular staff members, a man and a woman, are on duty at any given time. The guiding philosophy at Soteria is that the schizophrenic reaction is an altered state of consciousness in an individual who is experiencing a crisis iñ~.
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living. The disruptive psychotic experience is believed to have potential for reintegration and reconstitution, resulting in a more stable sense of self if the process is not prematurely aborted by neuroleptic drug use. By design, no neuroleptics are given during the subjects' first 6 weeks in the program. If there is no change in psychopathology by that time, drugs may then be prescribed. However, in the experimental samples reported here, only 3 percent received neuroleptics during their initial episodes of treatment. We have more completely described the research design (Mosher 1972) , staff (Mosher, Reifman, and Menn 1973) , milieu characteristics (Wendt et al., in press) , and I-year (Mosher, Menn, and Matthews 1975) and 2-year (Mosher and Menn 1978) followup results elsewhere.
Community Mental Health Center. The inpatient service of the community mental health center (CMHC) consists of one open and one locked ward of 30 beds each. About 250 patients are admitted each month. It is a well-staffed (1.5:1 staff-patient ratio) active treatment facility, which is oriented toward crisis intervention. High doses of neuroleptics are used, and rapid placement of patients in other parts of this relatively wellendowed county's treatment network is an immediate goal. Clinical decisions about neuroleptic drug use both during inpatient care and postdischarge are made by the individual psychiatrists responsible for the patient's care. The Soteria research team has no role in these decisions.
Research Methods
Sample Selection. All subjects are obtained from a screening facility, which is part of the CMHC complex containing our control ward,. Ap-proximately 600 new patients are seen there per month, of whom about 250 are hospitalized. Anyone meeting the following basic criteria is a potential study candidate:
• Clearly schizophrenic
• Deemed in need of hospitalization
• No more than one previous hospitalization for 2 weeks or less with a diagnosis of schizophrenia
• Age 16-30 (either sex)
• Unmarried, separated, widowed or divorced.
The selection criteria are designed to provide us with a relatively homogeneous sample of individuals diagnosed schizophrenic, but a group at risk for prolonged hospitalization or chronic disability. Early onset and being unmarried both predispose to chronic care (Strauss et al. 1977 ).
Treatment Assignment. Subjects meeting study selection criteria are idelltified without knowledge of the group to which they will ultimately be assigned. Study requirements are explained, and informed consent is obtained from the patient and his family, or significant other, if available. As only six residents can be accommodated in the experimental setting, intake is limited by bed availability. Therefore, consenting subjects are admitted to the experimental program if a bed is available. If no experimental bed is available, eligible consenting subjects are admitted to the comparison treatment group. Basically, this procedure results in treatment group assignment on a consecutively admitted, spaceavailable basis. It should be emphasized that our samples are remarkably similar on demographic and baseline psychiatric symptomatology variables.
Research Assessment. The measures below are a partial list of those COIT'-pleted at baseline (admission to the study) and at followup (6, 12, 18, and 24 months postadmission). All assessments are conducted by an independent research team that has no direct treatment responsibilities in either setting.
1. Baseline'.
• Diagnosis-As per DSM-II (American Psychiatric Association 1968). For a subject to be included in the study, three independent diagnoses of schizophrenia must be in agreement.
• Diagnostic symptoms-A checklist of seven symptoms. Four of seven symptoms are required for inclusion in the study (Cole, Klerman, and Goldberg 1964) .
• Certainty of diagnosis-A 7-point scale (Mosher, Pollin, and Stabenau 1971) .
• Mode of onset-Assesses acute! insidious onset types (Vaillant 1964 ).
• Paranoid!nonparanoid status-A short scale for rating paranoid schizophrenia (Venables and O'Connor 1959) .
• Inpatient Multidimensional Psychiatric Scale-A widely used symptom rating scale producing scores on 10 psychotic syndromes (Lorr, Klett, and McNair 1963) .
• Global severity-An overall measure of psychopathology.
• Brief social history form-A detailed description of a patient's and family's psychiatric and social history (Boothe, Schooler, and Goldberg 1972) .
2. Followup.
• Patient progress report-For each 6-monthly interval, information on the subject's medication history, use of other treatment, living arrangements (including any hospital SCHIZOPHRENIA readmissions), work status, soc~1 contacts, global severity, and improvement is obtained. Fleiss et al. (1976) and Klerman et al. (1974) . It has since been applied to schizophrenia outpatient data by Hogarty and Ulrich (1977) and Hogarty et al. (in press ). The life table provides a useful means of displaying longitudinal data for psychiatric patients. The subsequent application of various mathematical models allows the clinical questions related to change in the risk of relapse over N months, and the continuing advantages of program affil· iation, to be approached directly. The life table bases its estimates of risk on data from the total number of subjects in a study, including subjects administratively withdrawn and clinically relapsed, and provides data on the number of subjects at risk for a given interval of study, the proportion relapsed within an interval of time, and the cumulative proportion surviving throughout the study. Not only can the probability of surviving on a given treatment at a given interval of time be calculated, but the probability of ultimately surviving through subsequent periods of time can be determined as well. The pattern of relapse suggested by the life table contains the data that permits the "risk of relapse" to be disentangled from similar, but p0-tentially confounding, criteria such as "cumulative percent relapsed" or "months in the community." These issues are discussed in detail by Hogarty and Ulrich (1977) . A complete description of the analytic methods we used is available in Fleiss et al. (1976) , The life table method was used in this study to compare the probabilities of not being readmitted to residential care first between the two programs, Soteria and the CMHC, and then among three treatment subgroups from these programs, defined by pQs/discharge usage of major tranquilizers: subjects never-treated with neuroleptics (Soteria only); those withdrawn from neuroleptics (CMHC only); and subjects continuously maintained on neuroleptics (CMHC only). A patient's discharge from his original stay in the experimental/control facility is defined as the common starting point in the life table analyses. Although discharge varies considerably between the two programs in terms of length of time from patient's initial admission to the study, it is the most appropridte starting point as we are simply concerned with assessing the efficacy of two treatment programs, ach incorporating its own treatment modality, including short or long lengths of stays, rapid tranquil-,zallon with neuroleptics or minimal drug use, and high patient/staff ra-110. All patients were followed up from discharge until the occurrence 01. fnilure (defined as a readmission), Mantei (1966) . We will specifically focus our comparisons of cumulative probabilities of remaining continuously well at 6, 12, 18, and 24 months.
Methods of Analysis
Characteristics Associated With Relapse. A traditional approach to predicting number of mon ths to relapse, defined here as actual readmission to residential care, is to select the best possible subset of variables from a large pool of baseline psychopathological variables as well as social history and demographic variables, and relate this subset to time to relapse in a linear regression model. The problem that arises with this approach is that the dependent variable, number of months to relapse in this case, in linear regression should be normally distributed in order to obtain accurate results from the regression technique.
Because our data were bimodally distributed (i.e., into early relapsers and survivors), a different method, as suggested by Schooler et al. (1978) , and described below, was used to investigate po'ssible relationships between time to relapse and the group of baseline variables specified before. Our data were divided into three groupings of relapsers, omitting all administrative dropouts (N =4): (1) those who relapsed within the first 3 months after discharge (N =20); (2) those who relapsed between 4 months and 16 months after discharge (N =16); and (3) those who survived in the community for 17 months or more (N = 28). Sixteen months was chosen be-325 cause there was a 7-month gap after 16 months before another patient relapsed, and the number of cases lost due to administrative reasons was minimized.
For continuous baseline variables, we ran analyses of variance (ANOVAs), in the form of a 3 x 2 factorial model, i.e., three groupings of relapsers by two treatment groups, with the baseline variables as the dependent variable. We defined the treatment groups to be (1) the 50-teria cases (N = 32) regardless of drug usage postdischarge and CMHC cases (N = 36) and (2) the Soteria cases minus the patients who used drugs postdischarge (N = 26) and CMHC cases (N = 36). The first definition we will refer to as the program comparison and the second as the program by drug status comparison. The CMHC group in the program by drug status comparison could not be further broken down into the "withdrawn" and "continuous" groups as we did in the life table analyses because of the small number of cases in each cell. These analyses allow us to determine if there are differences among the three groupings by relapse in general, or differentially by treatment group, for each of the continuous variables in our pool of baseline variables.
For the categorical baseline variables, contingency tables were computed and significant relationships determined by chi-square or exact probabilities. For example, using the variable sex, a 3 x 2 table (relapse groupings by treatment groups) was computed for males, and then another for females.
Results
Data will be reported in two ways: (1) by program comparisons without regard to what specific postdischarge treatment modality individual clients received (drugs or not); (2) by program by drug status, which includes only Soteria subjects who received no drugs postdischarge and CMHC subjects who were either withdrawn (i.e., not on drugs continuously postdischarge) or maintained continuously on drugs postdischarge. 'c,jn!ergroup difference between Soteria nondrug and CMHC unmaintained group (p< .001).
• group difference between CMHC unmaintained and CMHC continuous groups (p <.0001 ). ---All Soteria subjects. N = 32.
----All CMCH subjects. N = 36. However, there were some significant main effect differences, i.e., regardless of program, among the three relapse groups as seen in table 6. The younger, less educated patients with lower occupational levels who stopped behaving at a com Farable level to their peers at a younger age were more likely to relapse at 3 months or less. This group of relapsers was significantly different on these four characteristics from thl? group who survived past 17 months. The 4-to 16-month relapse group also had significantly higher occupationaI levels than the early relapsers. Patient occupation is defined here as highest occupational level attained, not present occupation. This relationship can be seen more clearly if patient occupation is redefined as blue collar (unskilled, semiskilled, and skilled labor) and white collar life Table: Program by Drug Status Comparisons. Figure 2 reveals the Soteria nondrug group to have the highest survival rate overall during the 24-month study period. However, the CMHC withdrawn group has a curve similar to that of Soteria, although, at about 8 through 14 months, approximately a 20 percent difference in interval specific probabilities favoring the Soteria sample is found. The CMHC continuous drug group, on the other hand, has the lowest survival rates at every time interval. Mantel chi-squares "'" .....-----.\ show the 50teria sample to have a ..... significantly better chance of not having relapsed than the CMHC con tinuous group 'at 6, 12, 18, and 24 months (see table 4 ). likewise, the CMHC withdrawn group has significantly higher cumulative probabilities than the continuous drug group at 6 and 12 months, with the differences at 18 and 24 months dropping to the p:;;';;.10 level of significance. No significant differences were found when comparing the 50-teria nondrug and CMHC drug withdrawn samples.
50teria subjects. Because of the progressively smaller number of cases (rehospitalized subjects and administrative terminations are no longer included in the analysis), the differences favoring Soteria are not significant at 18 and 24 months, although the magnitude remains similar (tables 3 and 4). These differences occurred despite the fact that 50 percent of the CMHC sample was maintained on neuroleptics up to the point of readmission or until 24 0. tends to be at least twice as great for the maintenance drug group as for the drug-free group. Another interesting point to note is the difference found in the cumulative probability of remaining well for the Soteria sample as a whole and the 50teria sample in which subjects who received some neuroleptics whelming evidence in the psychiatric literature that maintenance treatment with neuroleptics reduces the risk of relapse. Our results were quite the opposite: Persons on maintenance drugs relapsed fastest and had a consistently higher risk of relapse throughout 24 months POStdischarge. In fact, the risk of relapse
Summary and Discussion
Data are reported from an ongoing stud v comparing the 2-year postdischarge probabilities of avoiding hospItal readmissions for two similar groups of schizophrenics treated in fWO different clinical settings. When wmparing the samples by program Affiliation, we found Soteria-treated (experimental) subjects to have a !tsser risk of subsequent readmissions than that of CMHC-treated (control) subjects. When the samples ,Were further divided by postdis-1 '0.,":",rge neuroleptic drug status, large : " erences in risk of relapse were . : r nd for the nondrug, withdrawn, : ,,' continuously maintained drug .ps. The risk of relapse through-• . 24 months was clearly lowest ,,"'; e Sateria nondrug sample and est for the CMHC patients tained on drugs before their ,relapse. The risk-of-relapse pat-;for the CMHC withdrawn , as similar to that of the 50-drug group. Our Findings 'sistent with the over- lapsed early (4 months). those who relapsed at some mid-point (betw~4 -16 months), and those who Sur. vived at least through 17 months postdischarge. We found persons who relapsed early to be young an.: have a lower occupational and edu. cationallevel, whereas late relap~n were generally older, had higher lX. cupational and educational levels. and stopped functioning at an Oldtr age as compared to others of their age and sex in their families and neighborhoods. Our survey of tht literature generally revealed thest variables to have little association with relapse (Gregory and DoWnlt 1968; Lewinsohn 1967 ) and the number and duration of previous hospitalizations to be the best pre· dictors of relapse {Buell and Anthony 1975; Rosenblatt and Meyer 1974; Strauss and Carpenter 1978! However, our findings are consistent with the general literature find:ngs that an early onset and poor social competence are associated with J'OOf outcomes (Strauss and Carpenter 1978) . That is, in our sample, early relapsers were younger upon their admission to the study (i.e., early onset) and had lower educational and occupational levels, correlates ,'li low social competence. As our cri· teria for sample selection excluded subjects with more than one pre"l' ous hospitalization of greater than ,: weeks' duration, we cannot relate our data to the previous hospitahu· tion findings reported in the liteu, ture. Also, because our experimentã nd control samples are relatively homogeneous (due to our sample selection procedures) and we have relatively small samples, we were not able to define differential pre<k tors of relapse hetween the two programs.
The question can be raised about these data as to whether or not tht 1
'ignif",n' d;if","" i n initi.,! dined by 6-10 percent at 6, 12,18, and 24 months.
In an attempt to identify baseline variables associated with relapse, we pooled the 50teria and CMHC samples and divided them into three categories of relapsers: those who re- 
